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Abstract
Background: The U.S. Food and Drug Administration (FDA) often approves new drugs based on trials that use
surrogate markers for endpoints, which involve certain trade-offs and may risk making erroneous inferences about
the medical product’s actual clinical effect. This study aims to compare the treatment effects among pivotal trials
supporting FDA approval of novel therapeutics based on surrogate markers of disease with those observed among
postapproval trials for the same indication.
Methods: We searched Drugs@FDA and PubMed to identify published randomized superiority design pivotal trials
for all novel drugs initially approved by the FDA between 2005 and 2012 based on surrogate markers as primary
endpoints and published postapproval trials using the same surrogate markers or patient-relevant outcomes as
endpoints. Summary ratio of odds ratios (RORs) and difference between standardized mean differences (dSMDs)
were used to quantify the average difference in treatment effects between pivotal and matched postapproval trials.
Results: Between 2005 and 2012, the FDA approved 88 novel drugs for 90 indications based on one or multiple
pivotal trials using surrogate markers of disease. Of these, 27 novel drugs for 27 indications were approved based
on pivotal trials using surrogate markers as primary endpoints that could be matched to at least one postapproval
trial, for a total of 43 matches. For nine (75.0%) of the 12 matches using the same non-continuous surrogate
markers as trial endpoints, pivotal trials had larger treatment effects than postapproval trials. On average, treatment
effects were 50% higher (more beneficial) in the pivotal than the postapproval trials (ROR 1.5; 95% confidence
interval CI 1.01–2.23). For 17 (54.8%) of the 31 matches using the same continuous surrogate markers as trial
endpoints, pivotal trials had larger treatment effects than the postapproval trials. On average, there was no
difference in treatment effects between pivotal and postapproval trials (dSMDs 0.01; 95% CI -0.15–0.16).
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Conclusions: Many postapproval drug trials are not directly comparable to previously published pivotal trials,
particularly with respect to endpoint selection. Although treatment effects from pivotal trials supporting FDA
approval of novel therapeutics based on non-continuous surrogate markers of disease are often larger than those
observed among postapproval trials using surrogate markers as trial endpoints, there is no evidence of difference
between pivotal and postapproval trials using continuous surrogate markers.
Keywords: Surrogate markers, Outcomes, Lifecycle evaluation, Regulation, U.S. Food and Drug Administration (FDA)
Background
The United States Food and Drug Administration (FDA)
review of new drug applications is guided by the Federal
Food, Drug, and Cosmetic Act, which suggests that drug
manufacturers submit “adequate and well-controlled” tri-
als providing evidence of drug safety and efficacy for mar-
keting approval (i.e., pivotal efficacy trials) [1]. Between
2002 and 2012, 49% of pivotal trials supporting approved
new drug indications used surrogate markers of disease as
primary endpoints (i.e., biomarkers or intermediate end-
points) that were deemed “reasonably likely” to predict
patient-relevant outcomes (e.g., mortality and morbidity)
[1, 2]. Furthermore, the majority of pivotal trials enrolled
fewer than 1000 patients with a follow-up of 6 months or
less [2].
The use of surrogate markers of disease as primary
endpoints can shorten the duration, size, and thus the
total financial cost of a pivotal trial [3–5]. However, trials
that use surrogate markers for endpoints also involve
certain trade-offs and may risk making erroneous infer-
ences and have diminished certainty about the medical
product’s actual clinical effect. Recent studies have
shown that commonly used surrogate markers can be
poor proxies for patient-relevant outcomes [6–8]. This
dilemma is reflected in recommendations for cautious
use of surrogate markers in drug assessment by many
international health technology appraisal agencies [9]. In
addition, shorter trials or trials that have been termi-
nated early can lead to biased treatment effects due to
large random fluctuations of the estimated treatment ef-
fect that can occur over shorter observation periods [10,
11]. Similarly, smaller trials may be more likely to result
in findings that appear more favorable compared with
true treatment effects [12–15]. Other dimensions of
lower methodological quality, including lack of double-
blinding, have also been associated with larger treatment
effects [16].
Perceptions of the potential treatment benefits of novel
drugs are often based on the results from pivotal trials
used during the FDA approval process. Evidence suggests
that the quantity and quality of postapproval trial evidence
varies substantially for drugs approved by the FDA based
on pivotal trials that use surrogate markers of disease as
primary endpoints [17]. Considering that there is growing
pressure for shorter regulatory evaluations and wider
adoption of surrogate markers as part of clinical trial de-
sign, it is necessary to determine whether the evidence
used to support the approval of novel therapeutics by the
FDA is reliable and potentially consistent in postapproval
trials evaluating the same drugs in diverse populations.
The objective of this study was to compare the treat-
ment effects among pivotal trials supporting FDA ap-
proval of novel therapeutics between 2005 and 2012
based on surrogate markers of disease and the treatment
effects observed among postapproval trials evaluating
the same surrogate markers of disease. We also aimed to
determine whether the treatment effects among pivotal
trials with surrogate markers as primary endpoints were
consistent with the treatment effects from postapproval
trials using patient-relevant outcomes. Results from this
work will inform regulatory decision-making and efforts
to promote the adoption of surrogate markers as part of
clinical trial design.
Methods
The protocol for this study was pre-specified prior to
performing any data analysis (see Additional file 1).
Identification of approved therapeutics
We used previously collected data on novel therapeutics
first approved by the FDA between 1 January 2005 and
31 December 2012 [2]. We did not consider additional
novel therapeutics approved after 31 December 2012 be-
cause insufficient time has passed since approval to
allow for completion and publication of postapproval
trials. The Drugs@FDA database was used to categorize
each novel therapeutic agent by year of approval and as
a pharmacologic entity (small molecule) or biologic.
FDA approval letters, which are hyperlinked in the
Drugs@FDA database, were then used to determine the
indications for which all novel therapeutic agents were
initially approved for use, whether agents were orphan
drugs, whether agents were approved through the accel-
erated approval pathway, and whether applications were
designated by the FDA for priority or standard review.
The World Health Organization’s Anatomic Therapeutic
Classification system was used to categorize each
indication into therapeutic areas (cancer, cardiovascular
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disease and diabetes mellitus, infectious disease, and
other) [18].
Identification of pivotal trials and primary trial endpoints
Pivotal trials were those labeled in FDA medical reviews
as “pivotal.” If FDA did not clearly specify the pivotal tri-
als, then trials that were described as essential to ap-
proval, were prioritized in the review, or were new
efficacy based trials provided as part of a resubmitted
application for approval were classified as pivotal [2, 17].
Primary trial endpoints were classified as patient-
relevant outcomes (e.g., mortality and morbidity), which
represent patient survival or function, or surrogate
markers of disease (e.g., changes in blood pressure),
which represent biomarkers expected to predict clinical
benefit, based on an established framework and an Insti-
tute of Medicine report [2, 19, 20]. Only therapeutics
that were approved exclusively based on a surrogate
marker were included in this evaluation. Study descrip-
tions, additional definitions, and inclusion and exclusion
criteria have been described in prior research [2].
Identification of pivotal trial publications
Publications of pivotal trials for novel therapeutic agents
approved between 2005 and 2011 have been described
in previously published research [21]. Briefly, the Scopus
database (Elsevier Inc.) was searched for the period from
April through October 2012 using the terms “[generic
drug name]” AND “clinical trial.” When necessary, the
manufacturer-designated trial identification numbers of
six or more characters were entered into the advanced
search feature of ClinicalTrials.gov. As described in prior
research, four criteria were used to identify matching
publications: study design, indication, intervention, and
intention-to-treat enrollment [21]. One author (JDW)
replicated this search process to locate publications for
the novel therapeutic agents approved in 2012.
Identification of postapproval trials
The international non-proprietary name of each drug
was searched for in Medline by two investigators to lo-
cate all postapproval prospective studies in humans that
used an active or placebo control as a comparator arm
and examined efficacy for the same therapeutic indica-
tion for which the drug was originally approved by the
FDA, as described in previous work [17]. The primary
trial endpoints of eligible postapproval trials were then
classified as patient-relevant outcomes, clinical scales, or
surrogate markers using the previously described estab-
lished framework and a recent Institute of Medicine re-
port [2, 19, 20]. Medline was utilized because it is the
largest database of biomedical journal articles that can
be searched freely using the PubMed system. Further-
more, the vast majority of clinicians and policymakers
rely on the PubMed system to learn about clinical trial
findings. Study descriptions, additional definitions, and
inclusions and exclusion criteria have been described in
prior research [17].
Study sample
One author (JDW) applied the inclusion and exclusion cri-
teria to all identified pivotal and postapproval trials. We ex-
cluded pivotal and postapproval trials that (1) were not
published, (2) were not interventional randomized trials,
(3) had an equivalence or non-inferiority design, (4) had
only one arm (i.e., no comparator groups) or evaluated
only different dosages of the same drug, (5) were crossover
trials, or (6) had no analyzable data. We excluded post-
approval trials that only had treatment arms where the
novel therapeutic of interest was combined with other
active interventions not considered in any of the corre-
sponding pivotal trials. Although individual pivotal trial
results are available in the FDA medical reviews on the
Drugs@FDA database, our study focused on the pivotal
trial data published in peer-reviewed biomedical journals.
This allowed for the construction of matched pairs of pub-
lished pivotal and postapproval trials. Doctors and policy-
makers often depend on the results from published clinical
trials. As such, published pivotal trials reflect the data avail-
able during the FDA approval process and are a source that
can be used to inform and influence real-world clinical
practice. Further justifying this decision, nearly 90% of
pivotal trials are published in the peer-reviewed biomedical
literature [21]. Potential matches and uncertainties were
discussed with an additional investigator (JSR).
Matching pivotal trials with postapproval trials
To create a sample of comparable published pivotal and
postapproval trials, one investigator (JDW), in discussion
with two others (OC and JSR), developed and undertook a
pre-specified matching process to pair each pivotal trial for
each drug and approved indication with one postapproval
randomized controlled trial. Prior to data collection, we de-
cided to match pivotal and postapproval trials individually.
Although multiple pivotal and postapproval trials could
have been pooled and then compared, we suspected that
matching individual trials would help simplify our analysis
while also maximizing the likelihood of identifying high-
similarity matches between pivotal and postapproval trials.
We established a hierarchical matching process based on a
pervious meta-epidemiological study comparing groups of
trials using surrogate and patient-relevant outcomes [6].
The vast majority of potential matches were discussed with
and reviewed by an additional investigator (JSR).
Postapproval trials using surrogate markers
When postapproval trials used surrogate markers for a
trial endpoint, a successful match of a pivotal and
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postapproval trial was based on the following hierarch-
ical matching process: use of (1) the same novel thera-
peutic for the same indication, (2) the same surrogate
marker that was the primary outcome in the pivotal
trial(s) used to form the exclusive basis of approval by
the FDA, (3) the same intervention dosage, and (4) the
same comparator. To ensure there was an adequate
number of potential matches, we did not require similar
population demographic and clinical characteristics. To
maximize the number of potential matches, pivotal and
postapproval trials using surrogate markers were re-
quired only to evaluate the same drug for the same indi-
cation with the same endpoint based on the same
surrogate marker (criteria 1 and 2). For criterion 2, we
allowed some flexibility in terms of timing (e.g., a pivotal
trial using a primary endpoint of sustained virologic re-
sponse at week 24 could be matched with a postapproval
trial using sustained virologic response at week 12) and
how the outcomes were measured (e.g., the time of day
a measurement was taken). For dosage, we looked for
treatment arms in the pivotal and postapproval trials
with the exact same therapeutic dosage (e.g., a pivotal
trial evaluating 750 mg of telaprevir twice a day could be
matched with a postapproval trial evaluating 1500 mg
once a day), but did not require the timing of the treat-
ment (e.g., multiple injections provided 7–9 h apart) or
the length of treatment (e.g., 12 weeks versus 24 weeks)
to be exactly the same. We allowed some flexibility in
terms of background therapies when matching pivotal
and postapproval trials (e.g., a pivotal trial evaluating lir-
aglutide in combination with metformin and thiazolidi-
nedione could be matched with a postapproval trial
evaluating liraglutide in combination with metformin
only). When possible, we matched pivotal and post-
approval trials that used the same comparator arm.
When pivotal trials had only a placebo comparator and
postapproval trials had only active comparators, we se-
lected the comparator arm in the postapproval trial with
the lowest dosage. When the pivotal and postapproval
trials were multi-armed, we selected the intervention
and comparator arms that were the most similar. When
pivotal trials had multiple postapproval trial matches, we
selected the trial with the longest follow-up time and the
largest number of intention-to-treat patients in the inter-
vention and comparator arms, as these trials would be
expected to bring more reliable results.
Postapproval trials using patient-relevant outcomes
(exploratory analyses)
When postapproval trials used patient-relevant out-
comes for the primary or secondary trial endpoint, a
successful match of a pivotal and postapproval trial re-
quired that they each evaluated the same drug for the
same indication. For potential matches, we further
identified whether the matched trials evaluated the same
intervention dosage and the same comparator (i.e., pla-
cebo, usual care, or active comparator).
Data extraction
For pivotal and postapproval trials, we recorded: total
sample size (intention to treat: all subjects initially
randomized, or modified intention to treat: all subjects
randomized who received at least one treatment), trial
duration (in weeks), blinding (double or triple blind, single
blind or open label), comparator arms included in the trial
(placebo only, active only, or both), center status (multi-
center or single center), funding (for profit, not for profit,
mixed, or none), and certain demographic characteristics
(percentage female, percentage non-Caucasian, and mean
or median age of study subjects). We also extracted the
number of patients and events in the selected treatment
and control arms, the absolute or relative effect sizes,
confidence intervals (CIs), standard deviations, standard
errors, or any other available data used to calculate the
endpoints based on surrogate markers or patient-relevant
outcomes. When necessary, an online digitizer (Web-
PlotDigitizer; https://automeris.io/WebPlotDigitizer/) was
used to extract approximate values from figures. Lastly, we
recorded whether the matched trial pairs using surrogate
markers fulfilled two, three, or four of the matching criteria
described above.
Data analyses
We used descriptive statistics to characterize the eligible
novel drugs approved by the FDA and to summarize the
design features of the pivotal trials and matched post-
approval trials. We used Wilcoxon’s signed rank and
McNemar’s exact tests to examine differences between
matched pairs. Descriptive analyses were performed using
R (version 3.4.0; The R Project for Statistical Computing)
and meta-analyses were performed using the metafor
package in R [22]. All statistical tests were two tailed and
used a type 1 error rate of 0.05.
Calculation of treatment effects
Standardized mean differences (Cohen’s d) were calculated
for all pivotal trials reporting continuous endpoints. For all
pivotal and postapproval trials with endpoints reporting
counts, proportions, or relative effect estimates (hereafter,
non-continuous endpoints), we calculated odds ratios or
approximated them from other relative risk measures pro-
vided. Similar to previous meta-epidemiological evalua-
tions, we assumed that reported relative risks or hazard
ratios were approximations to the odds ratio [6, 23]. The
direction of effect was standardized so that an odds ratio
above 1.0 and a positive standardized mean difference
(greater than 0.0) indicated a beneficial effect of interven-
tion compared to comparator arms.
Wallach et al. BMC Medicine  (2018) 16:45 Page 4 of 14
Primary analyses
When pivotal trials were matched only to a postapproval
trial using surrogate markers of disease for one of the trial
endpoints, we first separately combined the standardized
mean differences and odds ratios across pivotal and post-
approval trials using the DerSimonian and Laird proced-
ure for random effects. For each matched pair with a
continuous endpoint based on a surrogate marker, we
then estimated paired differences between standardized
mean differences. For each matched pair with non-
continuous surrogate markers of disease as trial end-
points, we converted odds ratios to natural log odds ratios
and then calculated the ratio of odds ratios. A positive
difference between standardized mean differences (greater
than 0.0) and a ratio of odds ratios greater than 1.0
implied greater (more beneficial) treatment effects in the
pivotal trials using a surrogate marker than in the post-
approval trials using a surrogate marker. Considering that
individual pivotal and postapproval trials were matched
based on two to four criteria, we calculated the variance
of each individual difference between standardized differ-
ence and ratio of odds ratio using two methods: (1) as-
suming that the pivotal and postapproval trials in the
matched pairs were independent and (2) assuming
between-study correlations of 0.5. If different results were
observed using the two methods, we planned to repeat the
calculations using correlation coefficients of 0.2, 0.3, and
0.4. If similar results were observed using the different
variance approximations, we reported the more conserva-
tive estimates (assuming that all matched pivotal and post-
approval trials were independent). Differences between
standardized mean differences and ratios of odds ratios
were separately combined using the DerSimonian and
Laird procedure for random effects. We performed our
analyses under the random-effects meta-analysis model
assumptions. In particular, we assumed that the true treat-
ment effect might be different between individual trials
(e.g., treatment effects could be higher among trials with
older or less healthy patients) [24]. All analyses were
repeated for pivotal and postapproval trial matches that
fulfilled at least three or all four of the matching criteria.
Secondary analyses
Standardized mean differences and associated variances
for all pivotal and postapproval trials reporting continu-
ous endpoints were transformed to natural log odds ra-
tios [25]. The ratio of odds ratios from all matched pairs
fulfilling two, three, or all four matching criteria were
then combined using the DerSimonian and Laird pro-
cedure for random effects.
Exploratory analyses
When pivotal trials were matched to postapproval trial
using patient-relevant outcomes for one of the trial
endpoints, the standardized mean differences from the
pivotal trials were transformed to natural log odds ratios
[25]. We then calculated the ratio of odds ratios. The
paired ratios of odds ratios were then combined using
the DerSimonian and Laird procedure for random ef-
fects. Ratios of odds ratios greater than 1.0 implied
greater (more beneficial) treatment effects in the pivotal
trials than in the postapproval trials. All variances were
calculated as described above.
Patient involvement
No patients were involved in setting the research question
or the outcome measures, nor were patients involved in
any other aspect of study design or implementation.
Results
Sample characteristics
Between 2005 and 2012, the FDA approved 88 novel
drugs for 90 indications based on one or multiple pivotal
trials using surrogate markers of disease. However, not
all indications had at least one published controlled
postapproval study using an active or placebo control
that examined efficacy for the same indication for which
the drug was first approved. In total, we identified 34 eli-
gible indications with a total of 93 published pivotal tri-
als that used a superiority or a superiority/non-
inferiority design and had at least one controlled post-
approval study (Fig. 1).
Fig 1 Sample construction for pivotal trials using surrogate markers
with matched postapproval trials using surrogate markers
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Postapproval trials using surrogate markers
We located 27 novel drugs for 27 indications based on
pivotal trials using surrogate markers as primary end-
points that could be matched to postapproval trials
evaluating the same drug and indication and using the
same surrogate markers as endpoints, for a total of 43
matches. The majority of the 43 matched trial pairs (one
pivotal trial matched to one postapproval trial) fulfilled
all four of the hierarchical matching criteria (33 of 43).
Only four (9.3%) had matched trials with different dos-
ages and comparator arms. Just under two-thirds of the
43 matched trial pairs used the same surrogate primary
endpoints (28 of 43, 65.1%). There were six (14.0%)
additional matched trials where the postapproval trial
evaluated the same surrogate marker but the primary
comparison was based on different intervention arms.
Characteristics for the matched pivotal and postapproval
trials, including intervention dosage, comparator, num-
ber of patients, and patient demographics, are included
in Additional file 2.
Most approvals for which we identified matched piv-
otal and postapproval trials were for pharmacologic
(small molecule) drugs for the treatment of chronic dis-
ease and were not granted orphan status, priority review,
or approved through the accelerated approval pathway
(Table 1). The most common therapeutic area was car-
diovascular disease and diabetes mellitus (11 of 27).
Compared with postapproval trials, pivotal trials had lar-
ger populations (P = 0.02), were more likely to be double
or triple blinded (P = 0.008), and were less likely to have
active only comparator arms (P = 0.04). Study duration
and total number of treatment arms (including control)
between the two groups of trials did not differ signifi-
cantly (P = 0.57 and 0.14, respectively) (Table 2).
Comparison of treatment effects
Pairs fulfilling at least two matching criteria
(primary analyses)
A total of 86 premarket pivotal and postapproval trials
were available for the paired analysis (43 matched pairs
of trials evaluating the same drug and indication and
Table 1 Characteristics of novel drugs approved by the FDA
based on pivotal trials using surrogate markers of disease
between 2005 and 2012 with at least one matched controlled
postapproval study
Characteristic N (%)
Total indications 27 (100.0)
Agent type
Pharmacologic 24 (88.9)
Biologic 3 (11.1)
Orphan status
No 24 (88.9)
Yes 3 (11.1)
Approval pathway
Regular 24 (88.9)
Accelerated 3 (11.1)
Priority review
Standard 19 (70.4)
Priority 8 (29.6)
Therapeutic area
Cardiovascular disease, diabetes mellitus 11 (40.7)
Infectious disease 6 (22.2)
Cancer 2 (7.4)
Other 8 (29.7)
Table 2 Characteristics of published, superiority, randomized,
pivotal trials of novel drugs first approved by the FDA
between 2005 and 2012 based on trials using surrogate
markers of disease as primary endpoints with at least one
postapproval match
Pivotal
trials
Postapproval
trials
Characteristics P valuea
Total studies 43 (100.0) 43 (100.0)
Allocation
Double or triple blind 39 (90.7) 31 (72.1) 0.008
Single blinded or open label 4 (9.3) 12 (27.9)
Number of arms
Median (interquartile range) 3 (2, 4) 2 (2, 4) 0.14b
Comparator options
Active only 9 (20.9) 17 (39.5) 0.04
Placebo only or active
and placebo
34 (79.1) 26 (61.5)
Center status
Multicenter 43 (100.0) 40 (93.0) 0.25
Single center 0 3 (7.0)
Funder type
Industry or mixed funding
that includes industry
40 (93.0) 38 (88.4) 0.69
All others (non-profit,
government, mixed
non-industry, none,
not specified)
3 (7.0) 5 (11.6)
Sample size
Total ITT or mITT, median
(interquartile range)
672 (390, 822) 395 (154, 735) 0.02b
Study duration
Duration in weeks, median
(interquartile range)
24 (10, 26) 24 (12, 26) 0.57b
aAnalyses based on McNemar’s exact test
bAnalyses based on Wilcoxon signed-rank test
ITT intention to treat (when available, all subjects randomized), mITT modified
intention to treat (all subjects randomized that received at least
one treatment)
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using the same surrogate markers as endpoints). Since
the results were similar using the different variance ap-
proximations, analyses were performed assuming that all
matched pivotal and postapproval trials were independent.
There were two matched pairs of trials that reported
hazard ratios. However, based on the data provided, we as-
sumed that these hazard ratios reasonably approximated
odds ratios. Furthermore, there were four matched pairs
fulfilling at least two matching criteria where the pivotal
trial had a placebo comparator and the postapproval trial
had an active comparator.
The majority (n = 9, 75%) of the 12 ratios of odds ra-
tios were greater than 1.0. On average, the treatment ef-
fects were 50% higher (more beneficial) in the pivotal
trials than in the matched postapproval trials (summary
ratio of odds ratios 1.50, 95% CI 1.01 to 2.23) (Figs. 2
and 3, Table 3).
Just over half (n = 17, 54.8%) of 31 of the differences
between the standardized mean differences were greater
than 0.0. On average, there was no difference between
standardized mean differences between the matched
pivotal and postapproval trials (summary difference be-
tween standardized mean differences 0.01, 95% CI -0.15
to 0.16) (Figs. 4 and 5, Table 3), although Fig. 6 suggests
there is a slight attenuation of continuous endpoints
based on surrogate makers in postapproval trials.
Pairs fulfilling at least three or all four matching criteria
When the analyses were repeated among the 39 pairs of
matched trials fulfilling at least three of the hierarchical
matching criteria, the ratio of odds ratios focusing on
trials with non-continuous surrogate markers of disease
as trial endpoints appeared to be somewhat attenuated to-
ward the null (summary ratio of odds ratios 1.45, 95% CI
0.99 to 2.14). The pooled standardized mean differences
from pivotal trials were 0.05 higher (more beneficial)
compared to the matched postapproval trials reporting
continuous endpoints based on surrogate markers
(summary difference between standardized mean differ-
ences 0.05, 95% CI -0.08 to 0.19). The findings were
similar when only the 33 matched pairs fulfilling all four
of the matching criteria were considered (Table 3).
Secondary analyses
After converting all of the standardized mean differences
to odds ratios, we estimated the ratio of odds ratios for
all 43 matched pairs. On average, the treatment effects
were 12% higher (more beneficial) in the pivotal trials
reporting endpoints based on surrogate markers than in
the postapproval trials reporting endpoints based on sur-
rogate makers (summary ratio of odds ratios 1.12, 95%
CI 0.88 to 1.42). Results were similar when analyses were
repeated for matched pairs that fulfilled at least three or
all four of matching criteria (Table 3).
Exploratory analyses: postapproval trials using patient-
relevant outcomes
We located three novel drugs for three indications based
on pivotal trials using surrogate markers as primary end-
points that could be matched to postapproval trials evalu-
ating the same drug and indication but using patient-
relevant outcomes as endpoints, for a total of three
matches, which is an insufficient number for a meta-
analysis. However, the individual odds ratios calculated
Fig. 2 Individual and summary odds ratios from pivotal and postapproval trials fulfilling at least two matching criteria and reporting non-continuous
endpoints
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from the pivotal trials based on surrogate markers were
between 160% and 1180% larger than the odds ratios cal-
culated from the postapproval trials based on patient-
relevant outcomes. One full comparison is described in
Box 1 for illustrative purposes and the remaining compari-
sons can be found in Additional file 3.
Discussion
Our study found that the treatment effects based on
non-continuous surrogate markers in pivotal trials are
larger than, and may overestimate, the treatment effects
based on the exact same non-continuous surrogate
markers when used in postapproval trials. Although we
did not observe any statistically significant differences
when we compared treatment effects observed based on
continuous surrogate markers, our findings highlight the
potential problem in the estimation of the magnitude of
treatment effects of drugs that are approved based on
surrogate markers of disease. Furthermore, we found
that many postapproval drug trials are not directly com-
parable to previously published pivotal trials, particularly
with respect to endpoint selection. In the exploratory
analyses, we found that the three postapproval trials with
patient-relevant outcomes had smaller treatment effects
than the pivotal trials using surrogate markers of disease
as trial endpoints.
Several reasons may explain why pivotal trials could
have larger treatment effects based on surrogate markers
compared with postapproval trials. First, pivotal trials
may have more stringent inclusion criteria, which could
lead to larger treatment effects, particularly if sicker or
less homogeneous patient populations are included in
trials. Evidence suggests that pivotal trials underrepre-
sent certain groups, including elderly patients and those
from racial and ethnic minorities [26]. Furthermore, pre-
market pivotal randomized controlled trials may be
more likely to exclude patients taking common medica-
tions and those with certain comorbidities [27]. Post-
approval trials, with potentially more relaxed patient
eligibility standards, may have attenuated treatment ef-
fects compared to pivotal trials if they evaluate drugs in
expanded populations or in combination with other in-
terventions. Second, our findings may coincide with the
observation that most large treatment effects become
smaller when additional studies are performed and evi-
dence is accumulated [15]. The data observed in one
pivotal trial may be at the far extreme of a distribution
of all possible treatment effects. Third, study selection
Fig. 3 Ratios of odds ratios comparing pivotal and postapproval trials fulfilling at least two matching criteria and reporting non-continuous
endpoints
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bias could explain why pivotal trials have large treatment
effect estimates. It is possible that controlled trials with
the largest treatment effects, selected from among all
studies submitted to the FDA, are more likely to be des-
ignated as essential (pivotal) during the drug approval
process. It is also possible that our finding of a statisti-
cally significant difference between treatment effects
from pivotal and postapproval trials is spurious. In par-
ticular, we approximated odds ratios for all non-
continuous surrogate markers, which are known to be
unstable when sample sizes are small.
Even though we found that pivotal trials reported larger
treatment effects when compared with postapproval trials
of non-continuous surrogate markers of disease as trial
endpoints, we did not observe any statistically significant
differences when we focused on continuous surrogate
markers. Overall, we are uncertain why there were differ-
ences between continuous and non-continuous surrogate
markers. While our findings could suggest that the evi-
dence used to support the approval of novel therapeutics
by the FDA is reliable and potentially consistent in post-
approval trials evaluating the same drugs in diverse popu-
lations, it is also possible that the treatment effects
reported in postapproval trials are exaggerated. It can be
argued that pivotal trials, which evaluate the efficacy of
novel therapeutics for the first time, face lower publica-
tion standards compared to postapproval trials. The au-
thors of postapproval trials evaluating primary endpoints
based on the same surrogate makers as previously pub-
lished pivotal trials may submit only manuscripts with
large statistically significant treatment effects to improve
the chances of getting published. As a result, the differ-
ences between treatment effects observed in our analyses
could be underestimated. In our sample, postapproval
Box 1: Illustrative example of a postapproval trial
using a patient-relevant outcome
Pivotal trials
In 2007, the FDA approved Tekturna (aliskiren) 150 mg and 300
mg tablets for the treatment of hypertension. The approval was
based on five randomized double-blind placebo-controlled piv-
otal trials evaluating the reduction in mean sitting diastolic
blood pressure (msDBP), a surrogate marker of disease, as the
primary efficacy outcome. For all five trials, we focused on the
comparison of aliskiren 300 mg with the placebo. We extracted
absolute changes in msDBP and calculated standardized mean
differences between treatment and placebo for all five studies.
After standardizing the standardized mean differences so that a
positive value (greater than 0.0) indicates a beneficial effect of
intervention, we transformed the standardized mean differences
to log odds ratios and combined them using the DerSimonian
and Laird procedure for random effects. We found a summary
odds ratio of 3.11 (95% CI 2.21 to 4.36), indicating the superiority
of aliskiren in terms of reducing msDBP.
Postapproval trials
There was one randomized postapproval study that compared
aliskiren (300 mg) with a placebo for the treatment of
hypertension that evaluated a patient-relevant outcome—a
composite endpoint of cardiovascular death, non-fatal myocar-
dial infarction, non-fatal stroke, and clinically significant heart
failure. Using the data available in the publication, we calculated
an odds ratio of 0.82 (95% CI 0.37 to 1.81). This odds ratio was
then transformed so that a value above 1.0 indicates a beneficial
effect of intervention (odds ratio 1.22; 95% CI 0.55 to 2.70).
Comparison of odds ratios
After calculating the ratio of odds ratios, we found that the
treatment effects were 160% higher in the five pivotal trials
using surrogate markers than in the one postapproval trial using
a patient-relevant outcome (ratio of odds ratios 2.6; 95% CI 1.05
to 6.23).
Table 3 Comparison of treatment effects of pivotal trial using
surrogate markers with matched postapproval trials using
surrogate markers: primary and sensitivity analyses
Summary difference between
standardized mean differences
or relative odds ratios (95% CI)
Method of analyses
At least two matching criteria (n = 43)
Reported non-continuous
endpoints
1.50 (1.01 to 2.23)
Reported continuous endpoints 0.01 (−0.15 to 0.16)
All standardized as odds ratios
(secondary)
1.12 (0.88 to 1.42)
At least three matching criteria (n = 39)
Reported non-continuous
endpoints
1.45 (0.99 to 2.14)a
Reported continuous endpoints 0.05 (−0.08 to 0.19)
All standardized as odds ratios
(secondary)
1.17 (0.95 to 1.45)
All four matching criteria (n = 33)
Reported non-continuous
endpoints
1.21 (0.89 to 1.64)
Reported continuous endpoints 0.06 (−0.10 to 0.21)
All standardized as odds ratios
(secondary)
1.13 (0.90 to 1.42)
A positive difference between standardized mean differences or ratio of odds
ratios >1.0 indicates a larger benefit of treatment compared to the comparator
in pivotal trials compared to postapproval trials. Pooled using DerSimonian
and Laird random-effects meta-analyses
CI confidence interval
a95% CI of 1.00 to 2.10 with a between-study correlation of 0.5
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trials were also smaller and less likely to be double or
triple blinded, which may indicate lower methodological
quality compared to pivotal trials. Previous evidence sug-
gests that lack or unclear double-blinding is associated
with an average of 13% exaggeration of treatment effects
(ratio of odds ratios 0.87; 95% CI 0.79 to 0.96) [13], and
that small trials typically have larger treatment effects [13,
15, 28–30]. Exaggerated postapproval treatment effects
due to lower methodological study quality could explain
why we did not observe statistically significant differences
between the treatment effects in many of our analyses.
Finally, postapproval trials using patient-relevant out-
comes were unlikely to evaluate the exact same interven-
tion in comparison to the exact same active or placebo
control as the pivotal trials with endpoints based on surro-
gate markers. To compare continuous and non-continuous
treatment effects for our exploratory analyses, we used a
common approach that allowed for conversion from
standardized mean differences to odds ratios [24, 25]. In
meta-analyses and meta-epidemiological evaluations, not
all studies use the same kind of data. Our transformations
were also informed by a previously published meta-
epidemiological study comparing continuous and non-
continuous outcomes [6]. Although this method leads to
some loss of power [25], we found that the pivotal trials
with endpoints based on surrogate markers reported larger
treatment effects than the three postapproval trials using
patient-relevant outcomes. In a prior study of 324 consecu-
tive cardiovascular trials published in major general med-
ical journals between 2000 and 2005, trials reporting
surrogate primary outcomes were more likely to report a
positive treatment effect than trials reporting patient-
relevant primary outcomes [31]. Evidence also suggests
that trials with large effects are more likely than other trials
to use laboratory-defined efficacy, such as endpoints based
on surrogate markers [15]. Similarly, a recent meta-
epidemiological study of randomized clinical trials pub-
lished in 2005 and 2006 in six high impact medical journals
found that trials with surrogate primary outcomes report
larger treatment effects than trials reporting patient-
relevant primary outcomes [6].
Implications of the study
Over the last few years, there have been new proposals
for increased reliance on smaller and shorter trials with
wider use of surrogate markers in the United States [32].
Fig. 4 Individual and summary standardized mean differences from pivotal and postapproval trials fulfilling at least two matching criteria and
reporting continuous endpoints
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The pressure to use surrogate markers has already re-
sulted in policy proposals. For instance, the 21st Century
Cures Act, which was introduced in the U.S. House of
Representatives in May 2015, encouraged the FDA to
rely more on surrogate markers instead of patient-
relevant outcomes [32]. In 2006, the Institute of
Medicine Report on the future of drug safety recom-
mended that the FDA monitor and evaluate the benefits
and risk of drug therapies throughout their entire mar-
ket life [33]. With this lifecycle evaluation approach,
drugs can be approved based on limited evidence, with
the understanding that they will continue to be
Fig. 5 Differences between standardized mean differences comparing pivotal and postapproval trials fulfilling at least two matching criteria and
reporting continuous endpoints
Fig. 6 Comparison of surrogate-based effect estimates from pivotal trials and post approval trials. One outlier not show on graph
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evaluated after approval. We found that when post-
approval trials do evaluate surrogate markers, the treat-
ment effects are smaller in comparison to the treatment
effects observed among pivotal trials using the same
endpoints based on surrogate markers of disease, specif-
ically for non-continuous surrogate markers. This may
mislead payers, policymakers, patients, and physicians
who need to determine the benefit of a medication in
clinical practice, particularly in comparison to other
available drugs and therapeutic approaches. If pivotal tri-
als using surrogate markers of disease as trial endpoints
have larger treatment effects that result from their strin-
gent eligibility criteria, efforts are necessary to ensure
that pivotal trials evaluate novel therapeutics in more di-
verse patient populations. Before promoting the broader
use of surrogate markers, an FDA advisory committee
may be necessary to examine why the same surrogate
markers for the same drugs do not always replicate
exactly in postapproval studies. Requirements for post-
approval trials should also be enhanced to strengthen
the lifecyle evaluation. In particular, investigators should
conduct postapproval studies that have adequate sample
sizes, study durations, and design characteristics, includ-
ing endpoints, to allow comparison to pivotal trials. The
FDA may need to enhance their enforcement of formal
empirical verification of surrogate markers, which can
help to establish the performance of a surrogate marker
and decide whether it should continue to be used as a
substitute and predictor of treatment benefit [8]. Lastly,
the FDA should continue to ensure that sponsors
complete postmarketing requirements (PMRs). Evidence
suggests that although sponsors are completing most
PMRs to schedule, certain PMRs are delayed and the FDA
continues to have problems with its ability to track PMRs
[34].
Limitations
Our study has certain limitations. First, we limited our
analysis to drugs evaluated by the FDA. Our results may
not be generalizable to other regulatory authorities, in-
cluding the European Medicine Agency, Health Canada,
and Japan’s Pharmaceutical and Medical Devices Agency.
Second, we restricted our analysis to studies that had
been published in the biomedical literature and indexed
in Medline. While this search may have excluded some
potential postapproval trials, it is unlikely that we missed
many studies not indexed in Medline that are used to
inform clinical practice [17].
Third, we attempted to maximize the comparability
between pivotal and postapproval trials by using a
hierarchical matching process. To ensure an adequate
number of matches, we required only that pivotal and
postapproval trials evaluated the same drug for the same
indication with the same endpoint based on a surrogate
marker. Even though the majority of our sample fulfilled
all four of the matching criteria, most matched trials will
have different eligibility criteria and/or methodological
characteristics, which can influence the treatment effects
observed. Furthermore, we did not consider the poten-
tial co-treatment effects when additional drugs were
studied that may have affected treatment effect sizes.
However, if additional matching criteria had been used,
the number of comparable pivotal and postapproval
matches would have been reduced. Furthermore, when
the analyses were repeated among the 33 matched pairs
fulfilling all four of the matching criteria, the ratio of
odds ratios focusing on trials with non-continuous sur-
rogate markers of disease as trial endpoints appeared to
be somewhat attenuated toward the null. This could
suggest that the different comparator groups (e.g., pla-
cebo or active control) may influence the magnitude of
the primary findings.
Fourth, with only 12 matched pivotal and postapproval
trials with non-continuous surrogate markers of disease
as trial endpoints in our sample, our findings are subject
to uncertainty. Even though odds ratios are one of the
most commonly reported measures of association or ef-
fect, relative risk calculations are unstable when sample
sizes are small.
Fifth, trials are generally powered to detect statistically
significant differences in their primary endpoint. Al-
though the endpoints based on surrogate markers in the
pivotal trials were all primary outcomes, to maximize
the number of matches, we considered endpoints based
on surrogate markers that were not the primary end-
point reported in the postapproval trials. As a result,
postapproval trials may not have been powered to detect
treatment effects based on the secondary surrogate
markers of interest.
Lastly, to locate an adequate number of matches, we
considered certain postapproval trials where it was
unclear whether they were performing superiority or
non-inferiority analyses.
Conclusions
The treatment effects from pivotal trials supporting FDA
approval of novel therapeutics based on surrogate
markers of disease are often larger than the treatment
effects observed among postapproval trials using surro-
gate markers as trial endpoints, specifically for non-
continuous surrogate markers. New proposals for
increased reliance on smaller and shorter trials with
surrogate markers carry the risk of demonstrating larger,
and potentially exaggerated, treatment effects, which may
ultimately lack reproducibility or generalizability. Policy-
makers, doctors, and patients should interpret treatment
effects based on surrogate markers of disease as primary
endpoints with caution, and in the absence of clinical
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outcomes, regulators and payers should focus on those
surrogate markers that have been validated.
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